Edwards Lifesciences (NYSE:EW) Stock Price Expected to Rise, Barclays Analyst Says

Edwards Lifesciences (NYSE:EW) had its price target increased by equities research analysts at Barclays from $110.00 to $120.00 in a research report issued on Thursday, Benzinga reports. The brokerage presently has an “overweight” rating on the medical research company’s stock. Barclays‘s price target indicates a potential upside of 20.88% from the company’s previous close.

EW has been the subject of a number of other reports. Raymond James Financial raised their price objective on shares of Edwards Lifesciences from $100.00 to $103.00 and gave the stock an “outperform” rating in a report on Friday, July 24th. Truist Financial set a $113.00 target price on shares of Edwards Lifesciences and gave the company a “buy” rating in a research note on Wednesday. UBS Group reissued a “buy” rating and issued a $110.00 price target (up from $90.00) on shares of Edwards Lifesciences in a research report on Thursday, October 8th. The Goldman Sachs Group raised their price target on shares of Edwards Lifesciences from $98.00 to $102.00 and gave the stock a “buy” rating in a research note on Tuesday, July 14th. Finally, Mizuho set a $120.00 price objective on Edwards Lifesciences in a report on Thursday. One investment analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and five have issued a Hold rating to the company’s stock. According to MarketBeat.com, Edwards Lifesciences has a consensus rating of “Moderate Buy” and an average target price of $105.32.

Edwards Lifesciences Stock Performance

EW traded down $0.10 on Thursday, hitting $99.27. 5,229,963 shares of the stock traded hands, compared to its average volume of 4,512,299. The firm has a market capitalization of $57.16 billion, a PE ratio of 57.04, a P/E/G ratio of 2.49 and a beta of 0.85. The company has a current ratio of 4.52, a quick ratio of 3.77 and a debt-to-equity ratio of 0.06. Edwards Lifesciences has a 52 week low of $74.66 and a 52 week high of $104.17. The business has a fifty day moving average price of $88.48 and a two-hundred day moving average price of $85.61.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Wednesday, November 4th. The medical research company reported $0.80 EPS for the quarter, beating analysts’ consensus estimates of $0.74 by $0.06. Edwards Lifesciences had a return on equity of 15.68% and a net margin of 15.43%. The business had revenue of $1.72 billion during the quarter, compared to analyst estimates of $1.68 billion. During the same period in the prior year, the company posted $0.67 earnings per share. Edwards Lifesciences’s revenue was up 10.5% on a year-over-year basis. On average, research analysts predict that Edwards Lifesciences will post 3.00 EPS for the current fiscal year.

Insider Activity

In related news, SVP Andrew M. Dahl sold 544 shares of the firm’s stock in a transaction on Monday, August 31st. The stock was sold at an average price of $91.06, for a total transaction of $49,536.64. Following the completion of the sale, the senior vice president directly owned 14,868 shares of the company’s stock, valued at $1,353,880.08. This trade represents a 3.53% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, VP Annette Brüls sold 2,644 shares of Edwards Lifesciences stock in a transaction on Friday, August 28th. The shares were sold at an average price of $89.98, for a total value of $237,907.12. Following the completion of the transaction, the vice president owned 17,984 shares of the company’s stock, valued at approximately $1,618,200.32. The trade was a 12.82% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 5,045 shares of company stock worth $451,596. Insiders own 0.31% of the company’s stock.

Institutional Trading of Edwards Lifesciences

A number of hedge funds and other institutional investors have recently made changes to their positions in EW. Pin Oak Investment Advisors Inc. bought a new position in shares of Edwards Lifesciences in the second quarter worth about $26,000. TrinityBridge Ltd bought a new stake in shares of Edwards Lifesciences during the second quarter valued at approximately $27,000. GK Wealth Management LLC acquired a new stake in shares of Edwards Lifesciences in the third quarter valued at approximately $26,000. RMG Wealth Management LLC acquired a new stake in shares of Edwards Lifesciences in the first quarter valued at approximately $26,000. Finally, Compass Financial Management LLC acquired a new stake in shares of Edwards Lifesciences in the second quarter valued at approximately $32,000. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Edwards Lifesciences News Roundup

Here are the key news stories impacting Edwards Lifesciences this week:

• Positive Sentiment: Edwards reported third-quarter adjusted EPS of $0.80 and revenue of $1.72 billion, topping estimates. Sales grew 11.2% year over year, supported by 8.8% growth in TAVR and a 45.6% surge in transcatheter mitral and tricuspid therapies (TMTT). The company raised its full-year adjusted EPS outlook to $2.97–$3.05, reinforcing expectations for continued growth. Q3 earnings call highlights
• Positive Sentiment: New PROGRESS Trial results found TAVR performed better than active surveillance for at-risk patients with moderate aortic stenosis, including fewer combined death or heart-failure outcomes, fewer heart-failure hospitalizations and improved quality of life. The findings could support earlier use of the procedure; the company also expects procedure volumes to benefit from expanded Medicare reimbursement. PROGRESS Trial data
• Positive Sentiment: Several firms raised price targets after the results. Piper Sandler and BTIG set targets of $115, Baird upgraded EW to “outperform” with a $116 target, and JPMorgan raised its target to $120. These actions signal improved analyst expectations. JPMorgan price target change
• Negative Sentiment: Management cautioned that more competition is coming in TAVR, which could pressure market share or pricing. RBC also said the PROGRESS findings may not meaningfully expand the TAVR market, tempering expectations for the trial’s commercial impact. CEO comments on TAVR competition

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation (NYSE:EW) is a medical technology company focused on therapies for structural heart disease and critical care. The company develops and manufactures products designed to treat conditions affecting the heart’s valves, including aortic, mitral and tricuspid valve disorders.

Its portfolio includes transcatheter aortic valve replacement systems, transcatheter mitral and tricuspid therapies, surgical heart valves and valve-repair technologies. Edwards also provides related delivery systems and other medical devices used by physicians in minimally invasive and open-heart procedures.

Founded in 1958 by Miles Lowell Edwards, the company is headquartered in Irvine, California, and serves healthcare providers and patients internationally.